Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised study of lopinavir/ritonavir vs darunavir/ritonavir monotherapy as simplification of PI/NNRTI triple therapy in HIV-1
2009-013287-39Phase 4Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Jul 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of darunavir, lopinavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Plasmatic HIV-1 viral load at 48 weeks. Started Jul 2009; status: completed.
02
Drugs
darunavirlopinavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2009-013287-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013287-39.